Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1096

Shown on this page

Current sort

Stored official records

Conditions: Cardiac Surgery, Sternotomy
Interventions: Bupivacain, ESP block, PIF block, Ultrasound; Drug · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 85 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Embolism
Interventions: Anticoagulation with heparin, EkoSonicTM Endovascular System; Drug · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Newark, Delaware + 22 more

Conditions: Breast Cancer
Interventions: No Radiation, Radiation; Other · Radiation
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 35 Years and older · Female only
Enrollment: 2,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 451
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more

Conditions: Asthma, Type 2 Asthma
Interventions: FeNO Breath Test; Diagnostic Test
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Interventions: Administration Kit, Cerliponase Alfa; Device · Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 16
States / cities: Little Rock, Arkansas • Orange, California • Aurora, Colorado + 12 more

Conditions: Urinary Bladder Cancer, Muscle-invasive
Interventions: Enfortumab Vedotin, Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]); Drug · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 39
States / cities: Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more

Conditions: Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions: Cordella™ Pulmonary Artery Sensor System; Device
Lead sponsor: Endotronix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more

Conditions: Adenoid Cystic Carcinoma, Breast Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Triple Negative Breast Cancer
Interventions: Emi-Le; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 26
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 20 more

Conditions: HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Laboratory Biomarker Analysis, Positron Emission Tomography; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 25
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more

Conditions: Food Allergy
Interventions: dupilumab, linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Tampa, Florida • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Primary Mitochondrial Disease
Interventions: KL1333, Placebo; Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Orange, California • San Diego, California • San Francisco, California + 15 more

Conditions: Pleuritis, Non-specific
Interventions: Corticosteroid, No Corticosteroid; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: New York, New York

About this Mount Sinai institution page

What this page lists: ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mount Sinai

Filter and sort this campus

Stored official records

ESP/PIF for Sternotomy

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Quantifying the Burden of Type 2 (T2) Inflammation in Asthma

Cerliponase Alfa Observational Study in the US

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis

About this Mount Sinai institution page